Quick Answer
Immix Biopharma, Inc. reported Cash and Equivalents of $93.93 million for fiscal year 2025.
Immix Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $93.93M | +431.2% |
| 2024 | $17.68M | +1.0% |
| 2023 | $17.51M | +30.3% |
| 2022 | $13.44M | -23.8% |
| 2021 | $17.64M | +4411.7% |
| 2020 | $391.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.95M | -19.0% | +37.0% |
| June 30, 2025 | $11.64M | -51.5% | -26.9% |
| March 31, 2025 | $15.92M | -45.7% | -10.0% |
| December 31, 2024 | $17.68M | +1.0% | -10.2% |
| September 30, 2024 | $19.69M | +0.6% | -17.9% |
| June 30, 2024 | $23.98M | +89.5% | -18.2% |
| March 31, 2024 | $29.32M | +155.8% | +67.4% |
| December 31, 2023 | $17.51M | +30.3% | -10.6% |
- Immix Biopharma, Inc. showed an increase of +431.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Immix Biopharma, Inc.’s cash and equivalents has grown by 23917.4% (from $391.1 thousand to $93.93 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: